Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Metabolic Dysfunction-Associated Liver Diseases
How does managing a patient with concomitant alcohol related liver disease impact your choice of therapies?
Related Questions
How does a patient who is PNPLA-3 positive (heterozygote or homozygote) impact how you formulate their therapeutic plan?
In a patient with low (or normal) BMI but findings of steatosis on imaging, no cardiometabolic comorbidities, and very elevated CAP scores, what are your next diagnostic and therapeutic steps to identify the cause of their steatosis and subsequent management?
What is your approach on the pursuit of bariatric surgery in a patient with advanced fibrosis?
What are your biggest takeaways from the MASH-TAG 2025 conference?
How does presence of clinically significant portal hypertension change patient prognosis in MASLD?
In patients with Met-ALD, how do you approach their treatment plan?
How would you approach GLP-1/GIP agonist use for MASLD management in a patient who had a prior episode of pancreatitis?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
In patients with MASLD/MASH, do you perform any cardiac testing to create a patient's risk profile, given that cardiac complications are the top cause of morbidity and mortality in this patient population (especially those with advanced fibrosis)?
What is your approach to the use of lipoprotein(a) as part of the cardiometabolic profile of a patient suspected to have or with MASLD/MASH?
